A double-blind, placebo-controlled multicenter study of tacrine for Alzheimer's disease. The Tacrine Collaborative Study Group.
about
The cholinergic hypothesis of Alzheimer's disease: a review of progressGalanin in Alzheimer's disease: neuroinhibitory or neuroprotective?Discovery and characterization of novel allosteric potentiators of M1 muscarinic receptors reveals multiple modes of activity.Current pharmacologic options for patients with Alzheimer's diseaseEfficacy and safety of rivastigmine in patients with Alzheimer's disease: international randomised controlled trialA novel approach to delayed-start analyses for demonstrating disease-modifying effects in Alzheimer's diseaseCholinesterase inhibition in Parkinson's diseaseRecommendations for the management of behavioral and psychological symptoms of dementia.Meta-analysis of continuous outcome data from individual patients.Factors that can affect the external validity of randomised controlled trials.Cholinesterase inhibitors: a therapeutic strategy for Alzheimer disease.Defining meaningful change in Alzheimer's disease trials: the donepezil experience.North of England evidence based guidelines development project: guideline for the primary care management of dementiaA distribution-based method for assessing the differences between clinical trial target populations and patient populations in electronic health records.Modulation of spontaneous and stimulation-evoked transmitter release from rat sympathetic neurons by the cognition enhancer linopirdine: insights into its mechanisms of action.Bioavailability and pharmacokinetic disposition of tacrine in elderly patients with Alzheimer's disease.Prevalence of potentially reversible dementias and actual reversibility in a memory clinic cohortDetecting patients with Alzheimer's disease suitable for drug treatment: comparison of three methods of assessmentPharmacotherapy of behavioral and psychological symptoms of dementia: time for a different paradigm?Drugs for dementia: the first year. An audit of prescribing practice.Designing human m1 muscarinic receptor-targeted hydrophobic eigenmode matched peptides as functional modulatorsTreatment of dementia with neurotransmission modulation.Cognitive outcomes after sertaline treatment in patients with depression of Alzheimer diseaseClinical trials and late-stage drug development for Alzheimer's disease: an appraisal from 1984 to 2014Pharmacotherapy in the treatment of Alzheimer's disease: an updateTacrine: first drug approved for Alzheimer's disease.Correlates of response to acetylcholinesterase inhibitor therapy in Alzheimer's disease.Therapeutic approaches to age-associated neurocognitive disordersBrain aging research at the close of the 20th century: from bench to bedside.Sensitivity and specificity of neuroimaging for the diagnosis of Alzheimer's disease.Galantamine facilitates acquisition of hippocampus-dependent trace eyeblink conditioning in aged rabbitsSize of the treatment effect on cognition of cholinesterase inhibition in Alzheimer's disease.Muscarinic acetylcholine receptor expression in memory circuits: implications for treatment of Alzheimer disease.Why do so many drugs for Alzheimer's disease fail in development? Time for new methods and new practices?Imaging and acetylcholinesterase inhibitor response in dementia with Lewy bodies.Inhibition of acetylcholinesterase by two genistein derivatives: kinetic analysis, molecular docking and molecular dynamics simulationCholinergic and glutamatergic drugs in Alzheimer's disease therapy.Rehabilitation drives enhancement of neuronal structure in functionally relevant neuronal subsetsEfficacy of tacrine and lecithin in mild to moderate Alzheimer's disease: double blind trial.Administration and scoring variance on the ADAS-Cog.
P2860
Q22242019-CB81180C-D427-428E-AFDB-8B94820D9463Q24601893-D7829152-248C-49F0-B0ED-A9734D7BBFA1Q24657902-8B377031-EF7B-4D91-8DBA-A9A43795DD47Q24800530-539EBE52-3B33-49D7-B6AF-09A51CFF33A9Q28343193-2407003F-0643-4477-9EA8-84B238C79268Q28544423-5C9E6DE1-C85D-4C4B-835A-F3D6F1CBB869Q28870519-E69FC00A-91EA-4B69-A8B6-64A0047D8157Q30327961-332C3237-FB18-4518-9A74-46C3C0C37BBCQ30657054-1D8FB6BB-94A1-4499-8EFA-E5CCADB08233Q33251918-FAA0253A-C2BA-4360-AAE8-F38839F26B68Q33637687-BE0382CB-2136-4288-B238-81A90D661B20Q33711100-1804781E-40FD-4960-B523-F7D4C8C3AFF7Q33791951-8D483859-0D6F-4E81-A604-0179BAB35074Q33845832-95495150-C999-407F-888D-E01D21529DF2Q33859793-F3F08E2C-7F31-45DF-8889-B1A8902AB752Q33921804-809B6A44-2EA7-4D2A-83D8-4A6D855C796CQ34029725-DA6DC84F-DDDB-4460-B3FB-5E9D72E0FC4AQ34052739-1582F7EA-A444-4EA1-8933-98E4B8D228F0Q34146983-FC4852FD-139B-4552-90A1-516ABE8EF822Q34150502-4AFFF82A-41E0-4807-96B4-699E10A9B013Q34184921-42D56929-6C82-4C94-970C-67AA39895F7BQ34266258-EF2BFF0E-E21E-4369-B61D-BC600DC7604CQ34303563-B4AD6CDD-7E0E-4440-A71D-5C173E99985DQ34408888-558C2945-14B2-4F2F-AB21-27DF14F40153Q34481842-7B69828B-2EDE-4066-81DD-F0E28B555FC8Q34724675-6D341AE0-090C-4704-8B5E-95CBC8F68A17Q35066849-22109B0A-A96D-4D1A-8D8B-369AFD6027F7Q35236387-EE68EABA-11B6-4B06-82C4-002F044F7668Q35236407-C374B7DE-1CCD-43B4-B32C-F6C675307F0CQ35236542-6E118193-0322-42CA-B947-F658CA7EE704Q35541457-911F0863-162B-410E-B63E-4286856B8D8DQ35748293-0B4DF02D-D3A9-4AB0-8D86-FFDAB371B417Q35998803-06C82A9B-BCF9-49B9-9C99-07403731DFF0Q36022784-5FEE5557-A122-4F31-837B-D0270655077CQ36124416-BE9DF92F-B1BE-4D8D-926C-FEB019FFEC0FQ36237626-72F3EB5B-7742-4180-8210-ADA152C1E8ACQ36257227-A97E1075-87DE-499F-B326-BD9EFD40B7EBQ36684649-C4876FAA-1E11-4544-A982-110ECC89DEA1Q36884943-6D8445BF-88E9-4A12-A042-B582A9F50320Q37306860-DCA5ED2C-DBFA-434C-A0A9-63C5CF51DE82
P2860
A double-blind, placebo-controlled multicenter study of tacrine for Alzheimer's disease. The Tacrine Collaborative Study Group.
description
1992 nî lūn-bûn
@nan
1992年の論文
@ja
1992年学术文章
@wuu
1992年学术文章
@zh
1992年学术文章
@zh-cn
1992年学术文章
@zh-hans
1992年学术文章
@zh-my
1992年学术文章
@zh-sg
1992年學術文章
@yue
1992年學術文章
@zh-hant
name
A double-blind, placebo-contro ...... ine Collaborative Study Group.
@en
A double-blind, placebo-contro ...... ine Collaborative Study Group.
@nl
type
label
A double-blind, placebo-contro ...... ine Collaborative Study Group.
@en
A double-blind, placebo-contro ...... ine Collaborative Study Group.
@nl
prefLabel
A double-blind, placebo-contro ...... ine Collaborative Study Group.
@en
A double-blind, placebo-contro ...... ine Collaborative Study Group.
@nl
P2093
P921
P1476
A double-blind, placebo-contro ...... ine Collaborative Study Group.
@en
P2093
Drachman DA
Schneider LS
Whitehouse PJ
Woolson RF
P304
P356
10.1056/NEJM199210293271801
P407
P577
1992-10-01T00:00:00Z